These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21056459)

  • 1. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
    Stamp LK; Zhu X; Dalbeth N; Jordan S; Edwards NL; Taylor W
    Semin Arthritis Rheum; 2011 Jun; 40(6):483-500. PubMed ID: 21056459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    Stamp LK; Khanna PP; Dalbeth N; Boers M; Maksymowych WP; Schumacher HR; Becker MA; MacDonald PA; Edwards NL; Singh JA; Simon LS; McQueen FM; Neogi T; Gaffo AL; Strand V; Taylor WJ
    J Rheumatol; 2011 Jul; 38(7):1462-6. PubMed ID: 21724717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    Morillon MB; Stamp L; Taylor W; Fransen J; Dalbeth N; Singh JA; Christensen R; Lassere M
    BMJ Open; 2016 Sep; 6(9):e012026. PubMed ID: 27650765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in measurement instruments for acute and chronic gout studies.
    Grainger R; Taylor WJ; Dalbeth N; Perez-Ruiz F; Singh JA; Waltrip RW; Schlesinger N; Evans R; Edwards NL; Sivera F; Diaz-Torne C; MacDonald PA; McQueen FM; Schumacher HR
    J Rheumatol; 2009 Oct; 36(10):2346-55. PubMed ID: 19820224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
    Stamp LK; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    J Rheumatol; 2018 Mar; 45(3):419-424. PubMed ID: 29247147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome domains for studies of acute and chronic gout.
    Schumacher HR; Taylor W; Edwards L; Grainger R; Schlesinger N; Dalbeth N; Sivera F; Singh J; Evans R; Waltrip RW; Diaz-Torne C; MacDonald P; McQueen F; Perez-Ruiz F
    J Rheumatol; 2009 Oct; 36(10):2342-5. PubMed ID: 19820223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
    Morillon MB; Christensen R; Singh JA; Dalbeth N; Saag K; Taylor WJ; Neogi T; Kennedy MA; Pedersen BM; McCarthy GM; Shea B; Diaz-Torne C; Tedeschi SK; Grainger R; Abhishek A; Gaffo A; Nielsen SM; Noerup A; Simon LS; Lassere M; Tugwell P; Stamp LK; Gout Working Group FTO
    Semin Arthritis Rheum; 2021 Dec; 51(6):1378-1385. PubMed ID: 34839932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20).
    Aati O; Taylor WJ; Siegert RJ; Horne A; House ME; Tan P; Drake J; Stamp LK; Dalbeth N
    Ann Rheum Dis; 2015 Dec; 74(12):2144-50. PubMed ID: 25114061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time to revise the normal range of serum uric acid levels?
    Desideri G; Castaldo G; Lombardi A; Mussap M; Testa A; Pontremoli R; Punzi L; Borghi C
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1295-306. PubMed ID: 24867507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group.
    Grainger R; Dalbeth N; Keen H; Durcan L; Lawrence Edwards N; Perez-Ruiz F; Diaz-Torne C; Singh JA; Khanna D; Simon LS; Taylor WJ
    J Rheumatol; 2015 Dec; 42(12):2460-4. PubMed ID: 25641895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.
    Vazquez-Mellado J; Peláez-Ballestas I; Burgos-Vargas R; Alvarez-Hernández E; García-Méndez S; Pascual-Ramos V; Rull-Gabayet M
    Clin Rheumatol; 2018 Jul; 37(7):1885-1894. PubMed ID: 29546696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and First Validation of a Disease Activity Score for Gout.
    Scirè CA; Carrara G; Viroli C; Cimmino MA; Taylor WJ; Manara M; Govoni M; Salaffi F; Punzi L; Montecucco C; Matucci-Cerinic M; Minisola G;
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1530-7. PubMed ID: 26815286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout.
    Dalbeth N; Phipps-Green A; House ME; Gamble GD; Horne A; Stamp LK; Merriman TR
    Arthritis Res Ther; 2015 Sep; 17(1):263. PubMed ID: 26391224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
    Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate testing in gout: why, when and how.
    Dalbeth N; Winnard D; Gow PJ; Boswell DR; Te Karu L; Lindsay K; Arroll B; Stamp LK
    N Z Med J; 2015 Aug; 128(1420):65-8. PubMed ID: 26367514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.